公开(公告)号：US20170224657A1

公开(公告)日：2017-08-10

申请号：US15382448

申请日：2016-12-16

申请人： BOARD OF REGENTS OF NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF UNIVERSITY OF NEVADA, RENO

发明人： Dean Burkin ,  Ryan Wuebbles

IPC分类号： A61K31/404 ,  A61K45/06

CPC分类号： A61K31/404 ,  A61K31/16 ,  A61K31/19 ,  A61K31/20 ,  A61K31/277 ,  A61K31/341 ,  A61K31/343 ,  A61K31/36 ,  A61K31/37 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4365 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/551 ,  A61K31/57 ,  A61K31/575 ,  A61K31/661 ,  A61K38/05 ,  A61K38/39 ,  A61K45/06

摘要： Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

公开(公告)号：US09701669B2

公开(公告)日：2017-07-11

申请号：US14912233

申请日：2014-08-18

申请人： Merck Sharp & Dohme Corp.

发明人： Zhiqiang Yang ,  Fengqi Zhang ,  Guizhen Dong ,  Sandra Lee Knowles ,  Milana Maletic

IPC分类号： A61K31/4427 ,  C07D405/06 ,  C07D405/14 ,  A61K45/06 ,  A61K31/4365 ,  A61K31/443 ,  A61K31/444 ,  A61K31/616

CPC分类号： C07D405/14 ,  A61K31/4365 ,  A61K31/443 ,  A61K31/444 ,  A61K31/616 ,  A61K45/06 ,  C07D405/06 ,  A61K2300/00

摘要： The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is —[C(Ra)(Rb)]x—[C(Rb)(Rb)]y—C(O)NH2, or —N(H)—[(CH2)]z—C(O)—NH2, W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

公开(公告)号：US20170173005A1

公开(公告)日：2017-06-22

申请号：US15127240

申请日：2015-03-27

申请人： Research Foundation of the City University of New York ,  Children's Medical Center Corporation

发明人： Debra Auguste ,  Marsha A. Moses ,  Peng Guo

IPC分类号： A61K31/4965 ,  A61K31/4365 ,  G01N33/574 ,  A61K9/14 ,  C12Q1/68 ,  A61K31/429 ,  A61K31/191

CPC分类号： A61K31/4965 ,  A61K9/14 ,  A61K31/191 ,  A61K31/429 ,  A61K31/4365 ,  A61K47/555 ,  A61K2121/00 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/70525

摘要： A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM˜1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

公开(公告)号：US09662307B2

公开(公告)日：2017-05-30

申请号：US14184425

申请日：2014-02-19

申请人： Amarin Pharmaceuticals Ireland Limited

发明人： Joseph S. Zakrzewski

IPC分类号： A61K31/20 ,  A61K31/202 ,  A61K31/045

CPC分类号： A61K31/232 ,  A61K31/045 ,  A61K31/047 ,  A61K31/10 ,  A61K31/145 ,  A61K31/19 ,  A61K31/194 ,  A61K31/202 ,  A61K31/22 ,  A61K31/275 ,  A61K31/351 ,  A61K31/365 ,  A61K31/366 ,  A61K31/41 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/4365 ,  A61K31/683 ,  A61K2300/00

摘要： The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

公开(公告)号：US20170128420A1

公开(公告)日：2017-05-11

申请号：US15319358

申请日：2015-06-23

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Kristina Oresic Bender ,  Aaron Puri ,  Aimee Shen ,  Matthew S. Bogyo

IPC分类号： A61K31/41 ,  C12Q1/04 ,  A61K31/496 ,  A61K31/167 ,  A61K9/50 ,  A61K31/437

CPC分类号： A61K31/41 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2846 ,  A61K9/5026 ,  A61K31/167 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/496 ,  A61K31/555 ,  C12Q1/04

摘要： Disclosed are methods and compositions for reducing toxicity associated with infection by Clostridium difficile by inhibiting Clostridium difficile toxin B (TcdB) and/or toxin A (TcdA). Such compounds include ebselen compounds, namely ebselen and its salts, ebselen functional analogues and ebselen structural analogues, as well as certain amide derivatives. This includes Formula I, e.g. 1-methyl-3-phenylpropylamine, Formula II, e.g., 2,2′-diselane-1,2-diylbis[N-(2,4-difluorophenyl)benzamide]; and Formula III, e.g. 2-(2-methoxy-5-methylphenyl)-1, 2-benzoselenazol-3-one. The present compositions may be comprised in a colon-retentive formulation that increases residence of and/or release of the compound in the area where the infection is active.

公开(公告)号：US20170121341A1

公开(公告)日：2017-05-04

申请号：US15275967

申请日：2016-09-26

申请人： Jiangsu Vcare PharmaTech Co., Ltd.

发明人： Hong-Bin Sun ,  Jiaqi Shan ,  Boyu Zhang ,  Fang Yuan

IPC分类号： C07D495/04

CPC分类号： C07D495/04 ,  A61K31/4365 ,  C07B2200/07

摘要： Optically active 2-hydroxytetrahydrothienopyridine derivatives represented by Formula I and pharmaceutically acceptable salts, preparation method and use in the manufacture of a medicament thereof are disclosed. The pharmacodynamic experiment results show that the present compounds of Formula I are useful for inhibiting platelet aggregation. The pharmacokinetic experiment results show that the present compound of Formula I can be converted in vivo into pharmacologically active metabolites and are therefore useful for inhibiting platelet aggregation. Therefore, the present compounds are useful for the manufacture of a medicament for preventing or treating thrombosis and embolism related diseases.

公开(公告)号：US20170119721A1

公开(公告)日：2017-05-04

申请号：US15350312

申请日：2016-11-14

申请人： Amarin Pharmaceuticals Ireland Limited

发明人： Joseph S. Zakrzewski

IPC分类号： A61K31/232 ,  A61K31/351 ,  A61K31/365 ,  A61K31/366 ,  A61K31/4365 ,  A61K31/275 ,  A61K31/145 ,  A61K31/41 ,  A61K31/42 ,  A61K31/4166 ,  A61K31/19 ,  A61K31/22 ,  A61K31/047 ,  A61K31/10 ,  A61K31/194 ,  A61K31/683

CPC分类号： A61K31/232 ,  A61K31/045 ,  A61K31/047 ,  A61K31/10 ,  A61K31/145 ,  A61K31/19 ,  A61K31/194 ,  A61K31/202 ,  A61K31/22 ,  A61K31/275 ,  A61K31/351 ,  A61K31/365 ,  A61K31/366 ,  A61K31/41 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/4365 ,  A61K31/683 ,  A61K2300/00

摘要： The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

公开(公告)号：US20170065587A1

公开(公告)日：2017-03-09

申请号：US15123030

申请日：2015-03-03

申请人： The Board of Regents for Oklahoma State University

发明人： LIN LIU ,  YUJIE GUO

IPC分类号： A61K31/517 ,  A61K31/422 ,  A61K31/473 ,  A61K31/4365 ,  A61K31/352 ,  A61K31/4196

CPC分类号： A61K31/517 ,  A61K9/0034 ,  A61K31/352 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4365 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4743 ,  A61K31/522

摘要： Methods and compositions for preventing and/or treating viral infections are provided. The methods involve administering an agent that stabilizes or enhances Axin1 activity, e.g. and agent that inhibits tankyrase. Administration of the agent stimulates or increases interferon activity, thereby preventing or lessening at least one symptom of virus infection. The virus infection may be caused by a respiratory virus such as influenza vims.

摘要翻译： 提供了用于预防和/或治疗病毒感染的方法和组合物。 所述方法包括施用稳定或增强Axin1活性的试剂，例如。 和抑制卡拉胶酶的药剂。 药剂的施用可刺激或增加干扰素活性，从而预防或减轻至少一种病毒感染症状。 病毒感染可能是由呼吸道病毒如流感病毒引起的。

公开(公告)号：US20170044181A1

公开(公告)日：2017-02-16

申请号：US15304612

申请日：2015-04-17

申请人： INSTITUT PASTEUR KOREA

发明人： Marc P. WINDISCH ,  Hee-Young KIM ,  Jaewon YANG ,  Jong Yeon HWANG ,  Suyeon JO ,  Jeongjin KWON ,  Dongsik PARK ,  Jihyun CHOI ,  Jaeheon LEE

IPC分类号： C07D495/04 ,  A61K31/4365 ,  A61K45/06

CPC分类号： C07D495/04 ,  A61K31/4365 ,  A61K45/06 ,  C07D211/14 ,  C07D211/44 ,  C07D211/58 ,  C07D295/12 ,  C07D333/68 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D487/04

摘要： The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

摘要翻译： 本发明涉及小分子化合物及其用于治疗疾病，特别是病毒性疾病，特别是丙型肝炎病毒（HCV）的用途。

公开(公告)号：US20170014343A1

公开(公告)日：2017-01-19

申请号：US15279848

申请日：2016-09-29

申请人： Jingjun Huang

发明人： Jingjun Huang

IPC分类号： A61K9/107 ,  A61K47/24 ,  A61K47/02 ,  A61K47/10 ,  A61K31/4365 ,  A61K47/44

CPC分类号： A61K9/107 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/4365 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44

摘要： The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, nm) of 100-500 nm, where the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc.

摘要翻译： 本公开提供具有100-500nm的平均液滴尺寸（强度平均值，nm）的即用型油/水乳液组合物，其中油相包含分散在药学上可接受的油中的氯吡格雷游离碱。 乳剂使用氯吡格雷游离碱或油中预先混合氯吡格雷游离碱作为起始原料，还可含有一种或多种赋形剂，如表面活性剂或助表面活性剂，渗透剂，pH调节剂，抗氧化剂，防腐剂，甜味剂 ，和/或悬浮剂等